Publications

At Ichnos Glenmark Innovation, we’re working to make real progress in science and medicine.
Explore our recent publications to discover how we’re shifting medicine forward.

DATEASSETTITLELEAD AUTHORJOURNAL
11 Dec 2023ISB 1442Poster: Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Kazandjian D. et al.American Society of Hematology Annual Meetingarrow_green
10 Dec 2023ISB 1342Poster: Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Kapoor P. et al.American Society of Hematology Annual Meetingarrow_green
10 Dec 2023ISB 2001Poster: A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma (RRMM)Sia H. et al.American Society of Hematology Annual Meetingarrow_green
05 Nov 2023GRC 54276Clinical Abstract: Phase 1 First In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Efficacy Of Grc 54276, A Novel HPK1 Thronine-Kinase Inhibitor, In Advanced Solid Tumours And Lymphomas.Doddihal H. et. al.European Hematology Associationarrow_green
22 May 2023ISB 1342Pre-clinical Characterization of ISB 1342, a CD38xCD3 T-cell Engager for Relapsed/Refractory Multiple MyelomaPerro M. et al.Bloodarrow_green
17 Apr 2023ISB 2001Overcoming Mechanisms of Escape from Treatments for Multiple Myeloma by ISB 2001, a first-in-Class Trispecific BCMA and CD38 targeted T Cell EngagerPerro M. et al.American Association for Cancer Research Annual Meetingarrow_green
12 Dec 2022ISB 1442Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple MyelomaJiang T. et al.American Society of Hematology Annual Meetingarrow_green
12 Dec 2022ISB 1442Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple MyelomaJiang T. et al.American Society of Hematology Annual Meetingarrow_green
11 Dec 2022ISB 1342Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)Mohan S. et al.American Society of Hematology Annual Meetingarrow_green
11 Dec 2022ISB 1342Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)Mohan S. et al.American Society of Hematology Annual Meetingarrow_green
11 Dec 2022ISB 1442Poster: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALLSammicheli S. et al.American Society of Hematology Annual Meetingarrow_green
11 Dec 2022ISB 1442Presentation: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALLSammicheli S. et al.Presentation at the American Society of Hematology Annual Meetingarrow_green
10 Dec 2022ISB 2001ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma by Targeting Two AntigensPerro M. et al.Presentation at the American Society of Hematology Annual Meetingarrow_green
28 Jun 2022Process DevelopmentOptimization of a Cell Culture Clarification Platform Process With the Aim of Boosting the Recovery of Bispecific AntibodiesMette R. et al.ESACT2022 Conferencearrow_green
28 Jun 2022Process DevelopmentIncreased Throughput in Upstream Development via Automated Feed Strategy Using Qubicon®Schmid S. et al.ESACT2022 Conferencearrow_green
27 Jun 2022Process DevelopmentAssessment Of The Impact Of The Milling Type And Production Site For Cell Culture Feed Production Le Moal M. et al.ESACT2022 Conferencearrow_green
10 Jun 2022ISB 1442ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies Sammicheli S. et al.EHA2022arrow_green
13 Apr 2022ISB 1442ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies Sammicheli S. et al.American Association for Cancer Research Annual Meetingarrow_green
10 Dec 2021ISB 1442Oral Presentation: Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma Sammicheli S. et al.American Society of Hematology Annual Meetingarrow_green
10 Dec 2021ISB 1442Oral Presentation: ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple MyelomaSammicheli S. et al.Bloodarrow_green
04 Jun 2021ISB 1342Poster:ISB 1342, A First-In-Class CD38 T Cell Engager for the Treatment of Relapsed Refractory Multiple MyelomaDoucey, M.American Society of Clinical Oncology Annual Meetingarrow_green
03 May 2021ISB 830Telazorlimab in Atopic Dermatitis: Phase 2b Study Shows Improvement at 16 WeeksSher, L.2021 Society for Investigative Dermatology Virtual Meetingarrow_green
28 Jan 2021Cell Line DevelopmentGeneration of homogeneous cell populations with tunable levels of transgene expressionSchlicht D. et al.Journal of Biotechnologyarrow_green
13 May 2020BEAT® Antibody Engineering PlatformA single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer speciesStutz C. et al.Journal of Biological Chemistryarrow_green
12 Sep 2019BEAT® Antibody Engineering PlatformSingle-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and developmentOllier R. et al.mAbsarrow_g</a>reen
06 Feb 2019ISB 830GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitisGuttman-Yassky E. et al.Journal of Allergy and Clinical Immunologyarrow_green
27 Apr 2017BEAT® Antibody Engineering PlatformImmunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodiesSkegro D. et al.Journal of Biological Chemistryarrow_green

13 Apr 2022
ISB 1442

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies

Sammicheli S. et al.

American Association for Cancer Research Annual Meeting


10 Dec 2021
ISB 1442

Oral Presentation: Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma

Sammicheli S. et al.

American Society of Hematology Annual Meeting


10 Dec 2021
ISB 1442

Oral Presentation: ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

Sammicheli S. et al.

Blood


04 Jun 2021
ISB 1342

Poster:ISB 1342, A First-In-Class CD38 T Cell Engager for the Treatment of Relapsed Refractory Multiple Myeloma

Doucey,

M. American Society of Clinical Oncology Annual Meeting


03 May 2021
ISB 830

Telazorlimab in Atopic Dermatitis: Phase 2b Study Shows Improvement at 16 Weeks

Sher, L.

2021 Society for Investigative Dermatology Virtual Meeting


28 Jan 2021
Cell Line

Development Generation of homogeneous cell populations with tunable levels of transgene expression

Schlicht D. et al.

Journal of Biotechnology


13 May 2020
BEAT® Antibody Engineering Platform

A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species

Stutz C. et al.

Journal of Biological Chemistry


12 Sep 2019
BEAT® Antibody Engineering Platform

Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development

Ollier R. et al.

mAbs


06 Feb 2019
ISB 830

GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis

Guttman-Yassky E. et al.

Journal of Allergy and Clinical Immunology


27 Apr 2017
BEAT® Antibody Engineering Platform

Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies

Skegro D. et al.

Journal of Biological Chemistry